Current:Home > reviewsEx-CEO of Nevada-based health care company Ontrak convicted of $12.5 million insider trading scheme -AssetTrainer
Ex-CEO of Nevada-based health care company Ontrak convicted of $12.5 million insider trading scheme
View
Date:2025-04-18 14:18:35
LOS ANGELES (AP) — The former CEO and chairman of Ontrak, a publicly traded health care company based in Nevada, was found guilty Friday of a multimillion-dollar insider trading scheme.
A federal jury in Los Angeles convicted Terren Scott Peizer, a resident of Puerto Rico and Santa Monica, California, of one count of securities fraud and two counts of insider trading.
In a statement announcing the conviction, the Justice Department described it as the first case it has prosecuted exclusively based on what is known as Rule 10b5-1, which allows company insiders to create a predetermined plan to sell shares while also setting limits on certain trading practices.
Authorities said Peizer violated some of those limits when he set up plans in 2021 to sell shares in order to avoid more than $12.5 million in losses, after he learned that Ontrak’s largest customer at the time was set to terminate its contract with the company based just outside of Las Vegas.
After the news later became public, Ontrak’s stock price dropped by more than 44%, authorities said.
“This is the Justice Department’s first insider trading prosecution based exclusively on the use of a trading plan, but it will not be our last,” said Deputy Assistant Attorney General Nicole M. Argentieri, who heads the Justice Department’s Criminal Division. “We will not let corporate executives who trade on inside information hide behind trading plans they established in bad faith.”
One of Peizer’s lawyers, David Willingham, said in an emailed statement that they will appeal, and that testimony at trial showed Peizer didn’t act in bad faith because he relied on the advice of his management team when he set up the trading plans.
“In our view, this result is a travesty of justice, as Terren Peizer is innocent of these charges,” Willingham said. “We will not rest until it is overturned.”
Peizer, 64, is scheduled to be sentenced in October. He stepped down as CEO last March after he was indicted.
He faces up to 25 years in prison for securities fraud, and up to 20 years for each count of insider trading.
veryGood! (73866)
Related
- This was the average Social Security benefit in 2004, and here's what it is now
- Native American Pipeline Protest Halts Construction in N. Dakota
- Shipping Group Leaps Into Europe’s Top 10 Polluters List
- Brain Scientists Are Tripping Out Over Psychedelics
- The city of Chicago is ordered to pay nearly $80M for a police chase that killed a 10
- Report Offers Roadmap to Cleaner Biofuels from Non-Food Sources
- Fewer abortions, more vasectomies: Why the procedure may be getting more popular
- Over half of car crash victims had drugs or alcohol in their systems, a study says
- US appeals court rejects Nasdaq’s diversity rules for company boards
- Rihanna's Latest Pregnancy Photos Proves She's a Total Savage
Ranking
- Taylor Swift Eras Archive site launches on singer's 35th birthday. What is it?
- Coast Guard Plan to Build New Icebreakers May Be in Trouble
- When COVID closed India, these women opened their hearts — and wallets
- Today’s Climate: September 7, 2010
- What to watch: O Jolie night
- Editors' pick: 8 great global stories from 2022 you might have missed
- UN Climate Summit Opens with Growing Concern About ‘Laggard’ Countries
- Why Alexis Ohanian Is Convinced He and Pregnant Serena Williams Are Having a Baby Girl
Recommendation
Where will Elmo go? HBO moves away from 'Sesame Street'
Matty Healy Resurfaces on Taylor Swift's Era Tour Amid Romance Rumors
Hillary Clinton Finally Campaigns on Climate, With Al Gore at Her Side
China to drop travel tracing as it relaxes 'zero-COVID'
Dick Vitale announces he is cancer free: 'Santa Claus came early'
In county jails, guards use pepper spray, stun guns to subdue people in mental crisis
Is lecanemab the Alzheimer's drug that will finally make a difference?
Psychedelic drugs may launch a new era in psychiatric treatment, brain scientists say